The FDA is currently reevaluating its recent decision to remove Eli Lillys obesity and diabetes medications, Zepbound and Mounjaro, from the shortage list, allowing compounding pharmacies to continue producing their versions temporarily
Over time, as you lose weight, your metabolism will slow down to compensate, he explained
Source- ET Pharma ( #PharmaNews #Semaglutide #GenericDrugs #Healthcare #IndiaBusiness #PharmaTrends Semaglutide Patents Expiring in India, Canada, Brazil Big News in Pharma: The "Weight-Loss Drug" Market is Opening Up
If the litigation moves forward, bellwether trials will help shape the outcome of future cases and potential settlements
Clinical trials show that approximately 14% of patients taking Wegovy experience headaches, compared to 10% on placebo